(BWAY) Brainsway - Ratings and Ratios
Neurostimulation, Treatments, Mental Health, Disorders, Stimulation Platform
BWAY EPS (Earnings per Share)
BWAY Revenue
Description: BWAY Brainsway July 13, 2025
BrainsWay Ltd. is a medical technology company that specializes in developing and marketing noninvasive neurostimulation treatments for various mental health disorders. The companys Deep Transcranial Magnetic Stimulation (DTMS) platform technology is used to treat a range of conditions, including depression, anxiety, and obsessive-compulsive disorders, among others. BrainsWay serves healthcare professionals and institutions in the field of psychiatry globally.
To evaluate the companys performance, we can look at key performance indicators (KPIs) such as revenue growth, customer acquisition costs, and research and development (R&D) expenses as a percentage of revenue. Given the companys expanding product offerings and growing presence in international markets, a high revenue growth rate is expected. The companys R&D expenses are likely significant, given the need for continuous innovation in the field of neurostimulation. A key metric to watch is the companys ability to increase its customer base, including psychiatrists, hospitals, and medical centers, and to drive adoption of its DTMS technology.
From a financial perspective, BrainsWays market capitalization is approximately $242 million, with a price-to-earnings (P/E) ratio of 58.18, indicating a relatively high valuation compared to its earnings. The forward P/E ratio is even higher, at 80.00, suggesting that investors expect significant earnings growth in the future. The return on equity (RoE) is 8.24%, which is a relatively modest return. To justify its valuation, the company will need to demonstrate strong revenue growth and expanding profit margins.
To further assess the companys prospects, it would be essential to analyze its competitive positioning, regulatory environment, and clinical trial data supporting its DTMS technology. The companys ability to secure FDA clearance for new indications and expand its global footprint will be critical to driving growth. Additionally, monitoring the companys cash burn rate and its ability to generate cash from operations will be crucial in evaluating its financial sustainability.
BWAY Stock Overview
| Market Cap in USD | 320m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 1999-10-06 |
BWAY Stock Ratings
| Growth Rating | 75.9% |
| Fundamental | 81.8% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 42.2% |
| Analyst Rating | 4.75 of 5 |
BWAY Dividends
Currently no dividends paidBWAY Growth Ratios
| Growth Correlation 3m | 67.4% |
| Growth Correlation 12m | 72.1% |
| Growth Correlation 5y | 22% |
| CAGR 5y | 70.06% |
| CAGR/Max DD 3y (Calmar Ratio) | 1.18 |
| CAGR/Mean DD 3y (Pain Ratio) | 3.57 |
| Sharpe Ratio 12m | -0.09 |
| Alpha | 69.97 |
| Beta | 0.250 |
| Volatility | 54.40% |
| Current Volume | 84.8k |
| Average Volume 20d | 48.6k |
| Stop Loss | 15.8 (-7.1%) |
| Signal | 0.55 |
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (5.34m TTM) > 0 and > 6% of Revenue (6% = 2.77m TTM) |
| FCFTA 0.17 (>2.0%) and ΔFCFTA 7.91pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 138.8% (prev 123.9%; Δ 14.94pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.21 (>3.0%) and CFO 23.1m > Net Income 5.34m (YES >=105%, WARN >=100%) |
| Net Debt (-61.8m) to EBITDA (8.14m) ratio: -7.59 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.51 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (20.3m) change vs 12m ago 35.13% (target <= -2.0% for YES) |
| Gross Margin 74.52% (prev 74.82%; Δ -0.31pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 52.02% (prev 55.51%; Δ -3.49pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 2.24 (EBITDA TTM 8.14m / Interest Expense TTM 2.80m) >= 6 (WARN >= 3) |
Altman Z'' -0.89
| (A) 0.57 = (Total Current Assets 89.5m - Total Current Liabilities 25.5m) / Total Assets 111.6m |
| (B) -0.85 = Retained Earnings (Balance) -95.2m / Total Assets 111.6m |
| (C) 0.07 = EBIT TTM 6.27m / Avg Total Assets 88.6m |
| (D) -2.23 = Book Value of Equity -97.0m / Total Liabilities 43.4m |
| Total Rating: -0.89 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 81.76
| 1. Piotroski 4.50pt = -0.50 |
| 2. FCF Yield 7.56% = 3.78 |
| 3. FCF Margin 40.66% = 7.50 |
| 4. Debt/Equity 0.09 = 2.50 |
| 5. Debt/Ebitda -7.59 = 2.50 |
| 6. ROIC - WACC (= 3.14)% = 3.92 |
| 7. RoE 8.97% = 0.75 |
| 8. Rev. Trend 97.92% = 7.34 |
| 9. EPS Trend 79.40% = 3.97 |
What is the price of BWAY shares?
Over the past week, the price has changed by +7.15%, over one month by +11.25%, over three months by +41.75% and over the past year by +69.76%.
Is Brainsway a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BWAY is around 18.91 USD . This means that BWAY is currently undervalued and has a potential upside of +11.17% (Margin of Safety).
Is BWAY a buy, sell or hold?
- Strong Buy: 3
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BWAY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 17.4 | 2.3% |
| Analysts Target Price | 17.4 | 2.3% |
| ValueRay Target Price | 20.8 | 22.3% |
BWAY Fundamental Data Overview October 27, 2025
P/E Trailing = 60.0893
P/E Forward = 46.729
P/S = 6.9381
P/B = 4.1615
Beta = 0.25
Revenue TTM = 46.1m USD
EBIT TTM = 6.27m USD
EBITDA TTM = 8.14m USD
Long Term Debt = 6.13m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 911.0k USD (from shortTermDebt, last quarter)
Debt = 6.13m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -61.8m USD (from netDebt column, last quarter)
Enterprise Value = 247.9m USD (319.7m + Debt 6.13m - CCE 78.0m)
Interest Coverage Ratio = 2.24 (Ebit TTM 6.27m / Interest Expense TTM 2.80m)
FCF Yield = 7.56% (FCF TTM 18.7m / Enterprise Value 247.9m)
FCF Margin = 40.66% (FCF TTM 18.7m / Revenue TTM 46.1m)
Net Margin = 11.60% (Net Income TTM 5.34m / Revenue TTM 46.1m)
Gross Margin = 74.52% ((Revenue TTM 46.1m - Cost of Revenue TTM 11.7m) / Revenue TTM)
Gross Margin QoQ = 75.20% (prev 74.64%)
Tobins Q-Ratio = 2.22 (Enterprise Value 247.9m / Total Assets 111.6m)
Interest Expense / Debt = 12.79% (Interest Expense 784.0k / Debt 6.13m)
Taxrate = 3.34% (70.0k / 2.10m)
NOPAT = 6.06m (EBIT 6.27m * (1 - 3.34%))
Current Ratio = 3.51 (Total Current Assets 89.5m / Total Current Liabilities 25.5m)
Debt / Equity = 0.09 (Debt 6.13m / totalStockholderEquity, last quarter 68.1m)
Debt / EBITDA = -7.59 (Net Debt -61.8m / EBITDA 8.14m)
Debt / FCF = -3.30 (Net Debt -61.8m / FCF TTM 18.7m)
Total Stockholder Equity = 59.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.79% (Net Income 5.34m / Total Assets 111.6m)
RoE = 8.97% (Net Income TTM 5.34m / Total Stockholder Equity 59.6m)
RoCE = 9.55% (EBIT 6.27m / Capital Employed (Equity 59.6m + L.T.Debt 6.13m))
RoIC = 10.18% (NOPAT 6.06m / Invested Capital 59.6m)
WACC = 7.04% (E(319.7m)/V(325.9m) * Re(6.94%) + D(6.13m)/V(325.9m) * Rd(12.79%) * (1-Tc(0.03)))
Discount Rate = 6.94% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 33.33 | Cagr: 11.11%
[DCF Debug] Terminal Value 80.17% ; FCFE base≈13.6m ; Y1≈15.6m ; Y5≈21.8m
Fair Price DCF = 19.82 (DCF Value 376.7m / Shares Outstanding 19.0m; 5y FCF grow 17.36% → 3.0% )
EPS Correlation: 79.40 | EPS CAGR: 394.3% | SUE: -2.91 | # QB: 0
Revenue Correlation: 97.92 | Revenue CAGR: 38.40% | SUE: 1.22 | # QB: 1
Additional Sources for BWAY Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle